Detail akcie Caribou Bio Rg online

Business Summary: Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Caribou Biosciences Inc revenues decreased 9% to $7.2M. Net loss increased 7% to $121.6M. Revenues reflect Biotechnology & Medical Research segment decrease of 72% to $2.2M, United States segment decrease of 75% to $1.8M, Rest of world segment decrease of 31% to $377K. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.26 to -$1.31.